Olema Pharmaceuticals Inc stock declines amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 Dec 25
Source: 144
Olema Pharmaceuticals Inc shares fell by 9.75% as the stock crossed below the 20-day SMA, reflecting a challenging trading session.
This decline occurs amid broader market strength, with the Nasdaq-100 up 1.27% and the S&P 500 up 0.54%. The movement suggests sector rotation as investors shift focus to other sectors, despite the overall positive market performance.
The implications of this decline may indicate a need for Olema Pharmaceuticals to reassess its market positioning and investor sentiment, especially in light of the current market dynamics.
Analyst Views on OLMA
Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 42.00 USD with a low forecast of 20.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.570
Low
20.00
Averages
42.00
High
60.00
Current: 24.570
Low
20.00
Averages
42.00
High
60.00
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
